Tags : Equillium

PharmaShots Weekly Snapshot (December 09-13, 2019)

Tuba Khan December 16, 2019

1. Pfizer’s Amsparity (biosimilar, adalimumab) Receives CHMP’s Positive Opinion for Inflammatory and Autoimmune Disorders Published: Dec 12, 2019 | Tags: Pfizer, Amsparity, biosimilar, adalimumab, Receives, CHMP, Positive Opinion, Inflammatory, Autoimmune […]readmore

Biotech

Equillium Expands its Exclusive Licensing Agreement with Biocon for Itolizumab

Tuba Khan December 13, 2019

Shots: Under the expanded collaboration, Equillium gets an exclusive right to develop and commercialize Biocon’s itolizumab in Australia and New Zealand. In May’2017, Biocon partnered with Equillium to develop a […]readmore

Tags : Equillium

PharmaShots Weekly Snapshot (December 09-13, 2019)

Equillium Expands its Exclusive Licensing Agreement with Biocon for Itolizumab

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Equillium

PharmaShots Weekly Snapshot (December 09-13, 2019)

Equillium Expands its Exclusive Licensing Agreement with Biocon for Itolizumab

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company